Contents
pdf Download PDF
pdf Download XML
71 Views
18 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 404 - 410
Comparison of Systemic Immune-Inflammation Index and Neutrophil-to-Lymphocyte Ratio for Identifying High Disease Activity in Rheumatoid Arthritis
 ,
 ,
 ,
 ,
 ,
1
Medical Officer, Sheikh Zayed Hospital.
2
Senior Register, Pak Medical and Dental College. AHS Buner.
3
Assistant professor, Department of Rheumatology, Khyber Teaching Hospital Peshawar.
4
Consultant Hematopathology, Prince Abdulaziz Bin Musaed Hospital, Northern Border Province Cluster, Ministry of Health Saudi Arabia.
5
Assistant professor, Institute of Biochemistry, University of Balochistan.
6
Assistant Professor, Baqai Institute of Hematology, Baqai Medical University.
Under a Creative Commons license
Open Access
Received
Oct. 11, 2026
Revised
Oct. 25, 2026
Accepted
Nov. 5, 2026
Published
Nov. 19, 2026
Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune condition that needs to be regularly assessed for disease activity. Systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) are available inflammatory markers that can help to determine high disease activity. Objective: To compare the diagnostic performance of SII and NLR in identifying high disease activity among patients with rheumatoid arthritis. Methods: A hospital-based analytical cross-sectional study was conducted at Sheikh Zayed Hospital Rahimyar Khan with 167 patients with RA during the period of 1st January to 30th June 2026. The patients were selected using consecutive sampling. Demographic, clinical, and laboratory parameters were noted. Disease activity was measured by DAS28-ESR. Complete blood counts (CBC) were used for the calculation of SII and NLR. Correlation and receiver operating characteristic (ROC) curve analyses were carried out, as well as logistic regression. Results: In the present study, 90 patients (53.9%) had high disease activity. Median SII and NLR were higher in the high-activity group than in the non-high-activity group. Among the parameters, SII was more significantly correlated with DAS28-ESR (r = 0.52) than with NLR (r = 0.44). The AUC values were 0.78 for SII and 0.73 for NLR. Conclusion: Both indices showed potential for identifying high RA disease activity, with numerically better discrimination by SII. 

Keywords
INTRODUCTION

Rheumatoid arthritis (RA) is a long-term autoimmune inflammatory condition of the synovial tissues, which results in chronic cartilage destruction and bone erosion and ultimately leads to functional disability.[1] It is mainly seen in females and has significant morbidity, lower quality of life, and higher health care utilization.[2] Over the past few decades, the burden of RA around the world has grown significantly, and it has become an important public health issue.[3]

 

The Global Burden of Disease 2021 Study estimated that there were around 17.6 million people with RA worldwide in 2020, and this is expected to rise to 31.7 million by 2050.[4] In addition, there were estimated to be 17.9 million prevalent cases, 1 million incident cases, and 3.08

 

million DALYs due to RA in 2021 globally.[5] The results highlight the increasing importance of having easy-to-use and reliable tools for monitoring and early detection of uncontrolled inflammation.

 

In patients with RA, a disease assessment is important to ensure that treatment is optimized and to prevent irreversible joint damage, leading to achieving long-lasting remission.[6] The Disease Activity Score in 28 Joints (DAS28), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI) are commonly used to assess disease severity and guide therapeutic decisions.[7] Of these, DAS28 includes clinical joint assessment and other variables, such as the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), depending on the version of the DAS28.[8] These are well-known and useful, but do need clinical knowledge to use, and inflammatory markers may not be reliably correlated with disease activity. Given this, there is a growing interest in easily available hematological parameters that could be used in conjunction with the more traditional assessment methods. The current guidelines are to monitor regularly and to use the treat-to-target approach to ensure better long-term clinical outcomes.

 

Two emerging inflammatory markers from routine complete blood counts, the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII), are emerging as potential markers of inflammation.[9] The ratio of absolute neutrophil count (ANC) to absolute lymphocyte count (ALC) is the NLR, which represents the level of activation of innate immune system components versus adaptive immune response components.[10] SII, on the other hand, involves an additional component of platelet activity associated with inflammation, as it is the product of multiplying the neutrophil count by the platelet count and dividing it by the lymphocyte count.[9] Both indices are cheap, readily available, and may be useful for the assessment of systemic inflammation. In a systematic review and meta-analysis of 18 studies and 3193 patients with RA, NLR values were significantly higher in active than in inactive patients (standardised mean difference = 0.37; 95% CI: 0.19–0.55; p < 0.001).[11] Likewise, an investigation of 257 women with RA and 71 healthy controls showed strong relationships between SII and several disease activity parameters, indicating that SII may contain more inflammatory information than NLR alone.[12]

 

Early detection of patients with high disease activity will continue to be a significant clinical challenge as ongoing inflammation is associated with rapid joint damage and poor outcomes. Both SII and NLR have shown links with disease activity, but the relative efficacy of the two indices in identifying patients with high disease activity has yet to be well established in different clinical populations. Importantly, the use of that of these two readily available indices that best discriminated, may lead to better preliminary risk stratification, earlier clinical evaluation and also facilitate cost-effective disease monitoring, especially in resource-limited healthcare settings. Thus, the present study was designed to compare the diagnostic performance of the systemic immune-inflammation index and neutrophil-to-lymphocyte ratio for determining high disease activity in rheumatoid arthritis patients, with the reference test of disease activity classification by the DAS28. Their associations with disease activity will also be examined, as will their sensitivity, specificity, and area under the receiver operating characteristic curve, to identify their usefulness as complementary indicators for routine clinical practice.

MATERIALS AND METHODS

Rheumatoid arthritis (RA) is a long-term autoimmune inflammatory condition of the synovial tissues, which results in chronic cartilage destruction and bone erosion and ultimately leads to functional disability.[1] It is mainly seen in females and has significant morbidity, lower quality of life, and higher health care utilization.[2] Over the past few decades, the burden of RA around the world has grown significantly, and it has become an important public health issue.[3]

 

The Global Burden of Disease 2021 Study estimated that there were around 17.6 million people with RA worldwide in 2020, and this is expected to rise to 31.7 million by 2050.[4] In addition, there were estimated to be 17.9 million prevalent cases, 1 million incident cases, and 3.08 million DALYs due to RA in 2021 globally.[5] The results highlight the increasing importance of having easy-to-use and reliable tools for monitoring and early detection of uncontrolled inflammation.

 

In patients with RA, a disease assessment is important to ensure that treatment is optimized and to prevent irreversible joint damage, leading to achieving long-lasting remission.[6] The Disease Activity Score in 28 Joints (DAS28), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI) are commonly used to assess disease severity and guide therapeutic decisions.[7] Of these, DAS28 includes clinical joint assessment and other variables, such as the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), depending on the version of the DAS28.[8] These are well-known and useful, but do need clinical knowledge to use, and inflammatory markers may not be reliably correlated with disease activity. Given this, there is a growing interest in easily available hematological parameters that could be used in conjunction with the more traditional assessment methods. The current guidelines are to monitor regularly and to use the treat-to-target approach to ensure better long-term clinical outcomes.

 

Two emerging inflammatory markers from routine complete blood counts, the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII), are emerging as potential markers of inflammation.[9] The ratio of absolute neutrophil count (ANC) to absolute lymphocyte count (ALC) is the NLR, which represents the level of activation of innate immune system components versus adaptive immune response components.[10] SII, on the other hand, involves an additional component of platelet activity associated with inflammation, as it is the product of multiplying the neutrophil count by the platelet count and dividing it by the lymphocyte count.[9] Both indices are cheap, readily available, and may be useful for the assessment of systemic inflammation. In a systematic review and meta-analysis of 18 studies and 3193 patients with RA, NLR values were significantly higher in active than in inactive patients (standardised mean difference = 0.37; 95% CI: 0.19–0.55; p < 0.001).[11] Likewise, an investigation of 257 women with RA and 71 healthy controls showed strong relationships between SII and several disease activity parameters, indicating that SII may contain more inflammatory information than NLR alone.[12]

 

Early detection of patients with high disease activity will continue to be a significant clinical challenge as ongoing inflammation is associated with rapid joint damage and poor outcomes. Both SII and NLR have shown links with disease activity, but the relative efficacy of the two indices in identifying patients with high disease activity has yet to be well established in different clinical populations. Importantly, the use of that of these two readily available indices that best discriminated, may lead to better preliminary risk stratification, earlier clinical evaluation and also facilitate cost-effective disease monitoring, especially in resource-limited healthcare settings. Thus, the present study was designed to compare the diagnostic performance of the systemic immune-inflammation index and neutrophil-to-lymphocyte ratio for determining high disease activity in rheumatoid arthritis patients, with the reference test of disease activity classification by the DAS28. Their associations with disease activity will also be examined, as will their sensitivity, specificity, and area under the receiver operating characteristic curve, to identify their usefulness as complementary indicators for routine clinical practice.

RESULTS

A total of 167 patients with RA were added to the study. The age group with the highest percentage (30.5%) of patients was 41-50 years. Most of the study population (74.3%) were females. In terms of BMI, 38.9% of the population were of normal weight and 36.5% were overweight. The majority of patients were nonsmokers (76.0%), and 34.7% had at least one comorbidity (Table 1).

 

The most frequently reported duration of disease (34.7%) was 2 - 5 years. Most patients were on disease-modifying antirheumatic drugs (88.0%), and 58.7% of patients were using corticosteroids. The highest disease activity group (DAS28-ESR) had 90 patients (53.9%), and the moderate disease activity group had 46 patients (27.5%). The rest of the patients were in the low disease activity or remission group (Table 2).

 

Patients with high disease activity had significantly higher counts of tender and swollen joints, DAS28-ESR, ESR, and CRP levels than patients with low disease activity (p<0.001). Likewise, the SII and NLR were significantly higher in the high disease activity group with median values of 890 vs. 580 (p<0.001) and 3.45 vs. 2.25 (p<0.001), respectively. There was also a significant increase in neutrophils and platelets and a decrease in lymphocytes. There were no statistically significant differences detected in age, BMI, or disease duration between the groups (Table 3).

 

Both SII and NLR demonstrated significant positive correlations with clinical and laboratory measures of rheumatoid arthritis disease activity. SII had a higher correlation with DAS28-ESR (r = 0.52) than with NLR (r = 0.44). Similar results were seen with ESR, CRP, tender joint count, swollen joint count, and PGC, and all reported correlations were statistically significant (p < 0.001) (Table 4).

 

ROC curve analysis revealed that the numerical area under the curve (AUC) of the SII was higher than that of NLR. SII showed a sensitivity and specificity of 78.9% and 70.1%, respectively, at the proposed cut-off value of 650, while NLR showed a sensitivity and specificity of 73.3% and 66.2%, respectively, at the proposed cut-off value of 2.80. These results indicated improved numerical discrimination by SII; however, we did not determine the statistical significance of the difference between the AUCs (Table 5).

 

In the multivariable logistic regression model, the SII and NLR remained independently associated with high RA disease activity, with positive associations. SII demonstrated an adjusted odds ratio of 1.18 per 100-unit increase (95% CI: 1.07–1.30; p = 0.001), while NLR showed an adjusted odds ratio of 1.39 per unit increase (95% CI: 1.08–1.79; p = 0.011). The model showed no statistically significant associations with other evaluated variables, including age, sex, BMI, disease duration, smoking history, comorbidities, or treatment history (Table 6).

 

 

 

 

 

 

 

 

 

 

 

Table 1. Demographic and Baseline Characteristics of Patients With Rheumatoid Arthritis (n = 167)

Demographic variables

Categories

Frequency (n)

Percentage (%)

Age (years)

18–30

24

14.4

 

31–40

39

23.4

 

41–50

51

30.5

 

51–60

35

21.0

 

>60

18

10.8

Gender

Male

43

25.7

 

Female

124

74.3

Body mass index (kg/m²)

Underweight (<18.5)

12

7.2

 

Normal weight (18.5–24.9)

65

38.9

 

Overweight (25.0–29.9)

61

36.5

 

Obese (≥30.0)

29

17.4

Smoking status

Current smoker

23

13.8

 

Former smoker

17

10.2

 

Never smoker

127

76.0

Presence of comorbidities

Yes

58

34.7

 

No

109

65.3

 

Table 2. Clinical Characteristics, Treatment History, and Disease Activity Classification (n = 167)

Variables

Categories

Frequency (n)

Percentage (%)

Disease duration

10 years

28

16.8

Current corticosteroid use

Yes

98

58.7

 

No

69

41.3

Current DMARD treatment

Yes

147

88.0

 

No

20

12.0

DAS28-ESR classification

Remission (3.2–5.1)

46

27.5

 

High (>5.1)

90

53.9

Primary outcome

High disease activity

90

53.9

 

Non-high disease activity

77

46.1

 

Table 3. Comparison of Clinical and Laboratory Parameters According to Disease Activity (n = 167)

Variables

High activity (n = 90)

Non-high activity (n = 77)

p-value

Age (years)

46.7 ± 11.5

45.8 ± 12.1

0.624

BMI (kg/m²)

26.8 ± 4.5

25.9 ± 4.2

0.185

Disease duration (years)

6.8 ± 4.1

5.9 ± 3.8

0.145

Tender joint count (0–28)

12 (9–16)

4 (2–7)

<0.001

Swollen joint count (0–28)

9 (6–12)

3 (1–5)

<0.001

Patient global assessment (0–100 mm)

72 ± 14

39 ± 16

<0.001

DAS28-ESR

6.3 ± 0.7

3.8 ± 1.0

<0.001

ESR (mm/hour)

48 (35–65)

25 (16–38)

<0.001

CRP (mg/L)

18.6 (10.4–32.5)

7.2 (3.5–13.8)

<0.001

Neutrophils (×10⁹/L)

5.8 ± 1.6

4.5 ± 1.3

<0.001

Lymphocytes (×10⁹/L)

1.7 ± 0.5

2.0 ± 0.6

0.001

Platelets (×10⁹/L)

315 ± 76

268 ± 65

<0.001

NLR

3.45 (2.70–4.60)

2.25 (1.70–3.00)

<0.001

SII

890 (670–1180)

580 (420–790)

<0.001

Table 4. Correlation of SII and NLR With Disease Activity and Inflammatory Parameters

Parameters

SII (r)

p-value

NLR (r)

p-value

DAS28-ESR

0.52

<0.001

0.44

<0.001

ESR

0.46

<0.001

0.39

<0.001

CRP

0.49

<0.001

0.42

<0.001

Tender joint count

0.40

<0.001

0.35

<0.001

Swollen joint count

0.43

<0.001

0.37

<0.001

Patient global assessment

0.38

<0.001

0.32

<0.001

Table 5. ROC Curve Analysis of SII and NLR for Identifying High Disease Activity

Diagnostic parameters

SII

NLR

Area under ROC curve (AUC)

0.78

0.73

95% CI for AUC

0.71–0.85

0.65–0.80

Optimal cutoff value

650

2.80

Sensitivity (%)

78.9

73.3

Specificity (%)

70.1

66.2

Positive predictive value (%)

75.5

71.7

Negative predictive value (%)

74.0

68.0

Youden index

0.49

0.40

 

Table 6. Multivariable Logistic Regression Analysis for High Disease Activity

Variables

Adjusted odds ratio (aOR)

95% CI

p-value

Age (per year)

1.01

0.98–1.04

0.510

Female sex

1.18

0.56–2.49

0.664

BMI (per kg/m²)

1.04

0.97–1.12

0.268

Disease duration (per year)

1.06

0.98–1.14

0.138

Current smoking

1.42

0.61–3.31

0.417

Presence of comorbidities

1.29

0.63–2.65

0.486

Current corticosteroid use

1.57

0.76–3.24

0.221

Current DMARD treatment

0.79

0.28–2.23

0.656

SII (per 100-unit increase)

1.18

1.07–1.30

0.001

NLR (per 1-unit increase)

1.39

1.08–1.79

0.011

DISCUSSION

In the present study, the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) were compared as markers for high disease activity (HDA) in patients with rheumatoid arthritis (RA). Of 167 patients, 53.9% had high disease activity (DAS28-ESR). Patients with high disease activity had higher median levels of both SII (890) and NLR (3.45) than those with low disease activity (580 and 2.25, respectively). The patterns were similar to those Satis (2021) found in 109 patients with RA, who observed significantly elevated SII levels in patients with active disease compared to those in remission (702.25 vs. 574.69; p = 0.030).[16] Likewise, Choe and Kim (2022) found links between changes in the hematological inflammatory indices and the DAS28-ESR in 24 weeks of treatment with Janus kinase inhibitors.[17] These studies confirmed the association of blood count–based inflammatory markers with RA disease activity, but there are some disparities in populations and classification of disease activity.

 

The positive correlation between NLR and disease activity in the present analysis is similar to the systematic review and meta-analysis carried out by Zinellu and Mangoni (2023). Their analysis revealed that, across 18 studies involving 3,193 patients with RA, there was a significant difference between the NLR of patients with active disease and patients with inactive disease (0.37; 95% CI: 0.19-0.55).[11] Choe et al. (2023) also analyzed haematological indices of 257 RA patients (71 controls). They found strong correlations between SII and a number of disease activity scores, but weaker correlations between NLR and DAS28-ESR that were not statistically significant.[12] The correlations in the present study were higher for SII (r =

 

0.52) and NLR (r = 0.44) in comparison. This variability may be partially attributed to variations in disease activity distribution, treatment exposure, and patient characteristics.

 

The present findings were also similar to those reported in Pakistan. In a study at the Federal Government Polyclinic Hospital in Islamabad, Khaliq and Shah (2024) found significantly higher mean SII in moderate to high disease activity as compared to the remission and low disease activity groups (1005.46 and 673.85, respectively). They concluded that there was a high correlation between SII and DAS28-ESR.[18] Previous studies did not consistently show as strong a relationship between these indices and disease activity. Amirpour et al. (2024) studied 250 RA patients and found that SII was significantly correlated with DAS28, but not NLR with DAS28. However, both of them were recognized as associated factors in their regression analysis. This contrasts with the results of the present study, in which both SII and NLR showed significant positive correlations with DAS28-ESR.[19] A study by Okutan et al. (2024) investigated 97 patients with RA and 51 healthy controls and observed that inflammatory indices are correlated with RA disease activity. They reported an AUC of 0.717 with a cutoff value of 611.45, sensitivity of 57.81%, and specificity of 60.61% for SII.[20]

 

In terms of diagnostic performance, the ROC analysis of the present study showed an AUC of 0.78 for SII and 0.73 for NLR. This difference in numbers indicated that SII might be able to offer slightly superior performance in discriminating high disease activity, but a statistical superiority would not be demonstrated until a paired comparison of AUCs was conducted. Li et al. (2026) studied 997 RA patients admitted to hospital, finding a positive correlation between SII and DAS28-ESR and DAS28-CRP for values > 260.36. Their findings, however, did not make a direct comparison to NLR, but described the correlation between SII and disease activity.[13] Importantly, Zhang et al. analyzed moderate to high activity, while here direct comparisons are limited to high disease activity.[21]

 

In multivariate analysis with selected clinical and demographic characteristics illustrated, the association of SII and NLR with high disease activity was still positive. These estimates are yet to be tested with patient-level data; however, both indices have components of neutrophils and lymphocytes. The study was also expected to have some methodological weaknesses. The cross-sectional design would not allow for analysis of temporal relations in data or treatment effects, and repeated sampling at one hospital might not be generalizable. In addition, SII and NLR values might be affected by other factors such as use of corticosteroid therapy, use of DMARDs, comorbidities, and other factors which may affect circulating blood cell count. The proposed diagnostic cut-off values would also be limited in their reliability because of the relatively small target sample size and lack of external validation. Overall, the literature available confirmed that these hematological indices were related to RA disease activity, and some authors found that the SII discriminated more numerically. However, these findings did not provide enough evidence to conclude that SII could be a substitute for NLR, traditional inflammatory markers, or any of the known disease activity composite scores. Thus, both indices may serve as possible complementary indices that need further validation.

 

Limitations

There are several limitations in the present study. First, the study was of a cross-sectional and single-center design, which made the findings difficult to generalize and precluded an evaluation of changes in inflammatory indices over time. Secondly, the sample size was fairly small, and the sampling method was non-probability consecutive sampling, which might have caused selection bias. Third, owing to the use of exclusion criteria, possible influences of medication, comorbidities, and individual differences in hematological parameters on SII and NLR values remained. Moreover, these indices were not evaluated for the treatment response and prediction of disease progression due to the lack of follow-up.

CONCLUSION

The findings suggested that both the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) were positively associated with rheumatoid arthritis disease activity. SII showed greater diagnostic accuracy, sensitivity, and specificity than NLR in the identification of high disease activity. But there was no proof of statistical superiority. Both indices appeared to be potentially useful, inexpensive, and readily available complementary markers for assessing rheumatoid arthritis disease activity. Multicenter prospective studies of larger size and external validation were recommended to confirm their diagnostic validity and clinical usefulness.

REFERENCES
  1. Jahid, M., K.U. Khan, and R.S. Ahmed, Overview of rheumatoid arthritis and scientific understanding of the disease. Mediterranean journal of rheumatology, 2023. 34(3): p. 284-291.
  2. Tang, K., et al., Global, regional and national trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the Global Burden of disease study 2021. RMD Open, 2025. 11(2): p. e005383.
  3. Finckh, A., et al., Global epidemiology of rheumatoid arthritis. Nature Reviews Rheumatology, 2022. 18(10): p. 591-602.
  4. Cheng, Y., T. Shao, and X. Chen, Prevalence of rheumatoid arthritis in China: variations and trends from the global burden of disease study 2021. Rheumatology and Immunology Research, 2025. 6(2): p. 99-109.
  5. Piovani, D., et al., The global burden of enteric fever, 2017–2021: a systematic analysis from the global burden of disease study 2021. EClinicalMedicine, 2024. 77.
  6. Theivendren, P., et al., Comprehensive Review of Rheumatoid Arthritis Treatment: Exploring Pre-and Post-Treatment Approaches and the Role of Conventional and Emerging Drugs. Next Research, 2026: p. 102555.
  7. Abubaker, D.A. and S.K. Media, A longitudinal evaluation of disease activity indicators in rheumatoid arthritis: Analyzing concordance and discrepancy between DAS28 and SDAI. Reumatología Clínica, 2026: p. 502289.
  8. Mohammadi-Kebar, Y., et al., Comparative study of DAS-28 ESR and DAS-28 CRP in determining the severity of disease activity in patients with rheumatoid arthritis. Int J Community Med Public Health, 2022. 9(2): p. 626.
  9. Islam, M.M., M.O. Satici, and S.E. Eroglu, Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turkish journal of emergency medicine, 2024. 24(1): p. 8.
  10. Abdul-Kareem, E.A.-Z., Evaluation of (Neutrophil-to-lymphocyte Ratio (NLR)) as an Inflammatory Immune Marker in Patients with Acute Infections and Comparison-with Healthy Subjects. Indonesian Journal on Health Science and Medicine, 2026. 3(1): p. 10.21070/ijhsm. v3i1. 438-10.21070/ijhsm. v3i1. 438.
  11. Zinellu, A. and A.A. Mangoni, Neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratio and disease activity in rheumatoid arthritis: A systematic review and meta‐analysis. European journal of clinical investigation, 2023. 53(2): p. e13877.
  12. Choe, J.-Y., C.U. Lee, and S.-K. Kim, Association between novel hematological indices and measures of disease activity in patients with rheumatoid arthritis. Medicina, 2023. 59(1): p. 117.
  13. Li, X., et al., Association between systemic immune-inflammation index and disease activity score 28 in patients with rheumatoid arthritis: a cross-sectional study. Scientific Reports, 2025. 16(1): p. 557.
  14. Gündüz, İ. and A. Karataş, CLASSIFICATION CRITERIA SETS FOR RHEUMATOID ARTHRITIS: HISTORICAL PERSPECTIVE AND CLINICAL IMPLICATIONS. Rheumatology Quarterly, 2025. 3(2): p. 40-48.
  15. Kannayiram, S., et al., Elevated DAS28-ESR in patients with rheumatoid arthritis who have comorbid fibromyalgia is associated more with tender joint counts than with patient global assessment or swollen joint counts: implications for assessment of inflammatory activity. Clin Exp Rheumatol, 2024. 42(5): p. 1083-1090.
  16. Satis, S., New inflammatory marker associated with disease activity in rheumatoid arthritis: the systemic immune-inflammation index. Current health sciences journal, 2021. 47(4): p. 553.
  17. Choe, J.-Y. and S.-K. Kim, Association between hematological indicesand disease activity in patients with rheumatoid arthritis treated with janus kinase inhibitors for 24 weeks. Medicina, 2022. 58(3): p. 426.
  18. Khaliq, T. and S.A. Shah, Systemic immune inflammation index-an emerging marker for rheumatoid arthritis disease activity. Official Journal of Pakistan Medical Association, Rawalpindi–Islamabad Rawalpindi–Islamabad Branch Jul–Sep 2024 Volume 49 Number 3, 2024. 49(3): p. 471.
  19. Amirpour, A., et al., The association between systemic immune inflammation index and disease activity in patients with rheumatoid arthritis. Romanian Journal of Rheumatology/Revista Romana de Reumatologie, 2024. 33(2): p. 81.
  20. Okutan, İ., et al., New inflammatory markers associated with disease activity in rheumatoid arthritis: pan-immune-inflammation value, systemic immune-inflammation index, and systemic inflammation response index. Reumatologia, 2024. 62(6): p. 439.
  21. Zhang, J., et al., CBC‑derived inflammatory indices for rheumatoid arthritis diagnosis and activity assessment: differential performance by serostatus. Frontiers in Immunology, 2026. 17: p. 1740898.

 

Recommended Articles
Research Article
Clinical Evaluation of Postoperative Nausea and Vomiting Among Patients Undergoing General Anaesthesia.
Published: 25/12/2019
Research Article
Antimicrobial Resistance in Complicated Urinary Tract Infections: A Retrospective Study in a Tertiary Care Hospital of Western Odisha
...
Published: 19/11/2026
Research Article
Assessment of Heart Rate Variability Among Medical Students During Academic Stress: A Repeated-Measures Observational Study
Published: 30/12/2025
Research Article
Geriatric Neurosurgery: Need of Developing A Practice Protocol-Experience In A Tertiary Care Hospital Of Western Odisha
...
Published: 18/11/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine